April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Improvement of Angiographic Findings of Polypoidal Choroidal Vasculopathy After Induction Phase of Ranibizumab Therapy
Author Affiliations & Notes
  • T. Hikichi
    Ohtsuka Eye Hospital, Sapporo, Japan
  • H. Ohtsuka
    Ohtsuka Eye Hospital, Sapporo, Japan
  • M. Higuchi
    Ohtsuka Eye Hospital, Sapporo, Japan
  • T. Matsushita
    Ohtsuka Eye Hospital, Sapporo, Japan
  • H. Ariga
    Ohtsuka Eye Hospital, Sapporo, Japan
  • S. Kosaka
    Ohtsuka Eye Hospital, Sapporo, Japan
  • R. Matsushita
    Ohtsuka Eye Hospital, Sapporo, Japan
  • K. Takami
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Footnotes
    Commercial Relationships  T. Hikichi, None; H. Ohtsuka, None; M. Higuchi, None; T. Matsushita, None; H. Ariga, None; S. Kosaka, None; R. Matsushita, None; K. Takami, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 516. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Hikichi, H. Ohtsuka, M. Higuchi, T. Matsushita, H. Ariga, S. Kosaka, R. Matsushita, K. Takami; Improvement of Angiographic Findings of Polypoidal Choroidal Vasculopathy After Induction Phase of Ranibizumab Therapy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):516.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the changes in angiographic findings in eyes with polypoidal choroidal vasculopathy (PCV) after one intravitreal injection of ranibizumab (0.5 mg) a month for 3 months.

Methods: : Fifty consecutive eyes of 50 Japanese patients with PCV who received one intravitreal injection a month for 3 months of ranibizumab were studied prospectively. All patients were followed with fluorescein and indocyanine green angiographies using Heidelberg Retina Angiograph and optical coherence tomography. Indocyanine green angiography (ICGA) findings were compared between baseline and 1 month after the third intravitreal injection.

Results: : In the baseline ICGA, polyp lesions and abnormal choroidal vessels were seen in all eyes except two eyes in which the abnormal choroidal vessels could not be detected because of retinal and subretinal hemorrhages. One month after the third injection, ICGA showed that the polyp lesions resolved in 12 (22%) eyes, improved in 22 (44%) eyes, and were unchanged or worse in 16 (32%) eyes. In 10 (20%) eyes, the small diameter of the abnormal choroidal vessels resolved or the diameter decreased. However, the abnormal choroidal vessels were unchanged or worse in 38 (80%) eyes, and all eyes had residual abnormal choroidal vessels. The mean visual acuity (VA) improved significantly from 0.67 to 0.47 logMAR (minimum angle of resolution) (P=0.001, Wilcoxon matched-pairs signed-ranks test). No adverse events developed during the follow-up period.

Conclusions: : Ranibizumab can improve VA and ICGA findings in eyes with PCV. Although polyp lesions tended to improve, residual abnormal choroidal vessels were present.

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×